| Literature DB >> 30262591 |
.
Abstract
The FDA approved moxetumomab pasudotox-tdfk, a CD22-directed recombinant immunotoxin, for patients with relapsed/refractory hairy cell leukemia who have not responded to at least two prior treatments, including a purine nucleoside analogue. ©2018 American Association for Cancer Research.Entities:
Year: 2018 PMID： 30262591 DOI： 10.1158/2159-8290.CD-NB2018-126
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397